Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: A plausible key to understanding failure of a clinical trial for Alzheimer's disease

Yoshiyuki Soeda, Marino Saito, Sumihiro Maeda, Kohki Ishida, Akira Nakamura, Shuichi Kojima, Akihiko Takashima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Alzheimer's disease pathology is characterized by extracellular deposits of amyloid-β (Aβ) and intracellular inclusions of hyperphosphorylated tau. Although genetic studies of familial Alzheimer's disease suggest a causal link between Aβ and disease symptoms, the failure of various Aβ-Targeted strategies to slow or halt disease progression has led to consideration of the idea that inhibition of tau aggregation might be a more promising therapeutic approach. Methylene blue (MB), which inhibits tau aggregation and rescue memory deficits in a mouse model of tauopathy, however, lacked efficacy in a recent Phase III clinical trial. In order to gain insight into this failure, the present study was designed to examine the mechanism through which MB inhibits tau aggregation. We found that MB inhibits heparin-induced tau aggregation in vitro, as measured by thioflavin T fluorescence. Further, MB reduced the amount of tau in precipitants recovered after ultracentrifugation of the aggregation mixture. Atomic force microscopy revealed that MB reduces the number of tau fibrils but increases the number of granular tau oligomers. The latter result was confirmed by sucrose gradient centrifugation: MB treatmentwas associated with higher levels of granular tau oligomers (fraction 3) and lower levels of tau fibrils (fractions 5 and 6). We previously demonstrated that the formation of granular tau oligomers, rather than tau fibrils, is essential for neuronal death. Thus, the fact that MB actions are limited to inhibition of tau fibril formation provides a mechanistic explanation for the poor performance of MB in the recent Phase III clinical trial.

Original languageEnglish
Pages (from-to)1677-1686
Number of pages10
JournalJournal of Alzheimer's Disease
Volume68
Issue number4
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Methylene Blue
Alzheimer Disease
Clinical Trials
Phase III Clinical Trials
Tauopathies
Atomic Force Microscopy
Ultracentrifugation
Amyloid Plaques
Memory Disorders
Centrifugation
Sucrose
Disease Progression
Heparin
Fluorescence
Pathology

Keywords

  • Alzheimer's disease
  • Clinical trial
  • Granular tau oligomer
  • Inhibitor
  • Methylene blue
  • Oligomer
  • Protein aggregation
  • Tau protein

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers : A plausible key to understanding failure of a clinical trial for Alzheimer's disease. / Soeda, Yoshiyuki; Saito, Marino; Maeda, Sumihiro; Ishida, Kohki; Nakamura, Akira; Kojima, Shuichi; Takashima, Akihiko.

In: Journal of Alzheimer's Disease, Vol. 68, No. 4, 01.01.2019, p. 1677-1686.

Research output: Contribution to journalArticle

Soeda, Yoshiyuki ; Saito, Marino ; Maeda, Sumihiro ; Ishida, Kohki ; Nakamura, Akira ; Kojima, Shuichi ; Takashima, Akihiko. / Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers : A plausible key to understanding failure of a clinical trial for Alzheimer's disease. In: Journal of Alzheimer's Disease. 2019 ; Vol. 68, No. 4. pp. 1677-1686.
@article{36ed9b1d203240a0b455339d6589d02c,
title = "Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: A plausible key to understanding failure of a clinical trial for Alzheimer's disease",
abstract = "Alzheimer's disease pathology is characterized by extracellular deposits of amyloid-β (Aβ) and intracellular inclusions of hyperphosphorylated tau. Although genetic studies of familial Alzheimer's disease suggest a causal link between Aβ and disease symptoms, the failure of various Aβ-Targeted strategies to slow or halt disease progression has led to consideration of the idea that inhibition of tau aggregation might be a more promising therapeutic approach. Methylene blue (MB), which inhibits tau aggregation and rescue memory deficits in a mouse model of tauopathy, however, lacked efficacy in a recent Phase III clinical trial. In order to gain insight into this failure, the present study was designed to examine the mechanism through which MB inhibits tau aggregation. We found that MB inhibits heparin-induced tau aggregation in vitro, as measured by thioflavin T fluorescence. Further, MB reduced the amount of tau in precipitants recovered after ultracentrifugation of the aggregation mixture. Atomic force microscopy revealed that MB reduces the number of tau fibrils but increases the number of granular tau oligomers. The latter result was confirmed by sucrose gradient centrifugation: MB treatmentwas associated with higher levels of granular tau oligomers (fraction 3) and lower levels of tau fibrils (fractions 5 and 6). We previously demonstrated that the formation of granular tau oligomers, rather than tau fibrils, is essential for neuronal death. Thus, the fact that MB actions are limited to inhibition of tau fibril formation provides a mechanistic explanation for the poor performance of MB in the recent Phase III clinical trial.",
keywords = "Alzheimer's disease, Clinical trial, Granular tau oligomer, Inhibitor, Methylene blue, Oligomer, Protein aggregation, Tau protein",
author = "Yoshiyuki Soeda and Marino Saito and Sumihiro Maeda and Kohki Ishida and Akira Nakamura and Shuichi Kojima and Akihiko Takashima",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-181001",
language = "English",
volume = "68",
pages = "1677--1686",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers

T2 - A plausible key to understanding failure of a clinical trial for Alzheimer's disease

AU - Soeda, Yoshiyuki

AU - Saito, Marino

AU - Maeda, Sumihiro

AU - Ishida, Kohki

AU - Nakamura, Akira

AU - Kojima, Shuichi

AU - Takashima, Akihiko

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Alzheimer's disease pathology is characterized by extracellular deposits of amyloid-β (Aβ) and intracellular inclusions of hyperphosphorylated tau. Although genetic studies of familial Alzheimer's disease suggest a causal link between Aβ and disease symptoms, the failure of various Aβ-Targeted strategies to slow or halt disease progression has led to consideration of the idea that inhibition of tau aggregation might be a more promising therapeutic approach. Methylene blue (MB), which inhibits tau aggregation and rescue memory deficits in a mouse model of tauopathy, however, lacked efficacy in a recent Phase III clinical trial. In order to gain insight into this failure, the present study was designed to examine the mechanism through which MB inhibits tau aggregation. We found that MB inhibits heparin-induced tau aggregation in vitro, as measured by thioflavin T fluorescence. Further, MB reduced the amount of tau in precipitants recovered after ultracentrifugation of the aggregation mixture. Atomic force microscopy revealed that MB reduces the number of tau fibrils but increases the number of granular tau oligomers. The latter result was confirmed by sucrose gradient centrifugation: MB treatmentwas associated with higher levels of granular tau oligomers (fraction 3) and lower levels of tau fibrils (fractions 5 and 6). We previously demonstrated that the formation of granular tau oligomers, rather than tau fibrils, is essential for neuronal death. Thus, the fact that MB actions are limited to inhibition of tau fibril formation provides a mechanistic explanation for the poor performance of MB in the recent Phase III clinical trial.

AB - Alzheimer's disease pathology is characterized by extracellular deposits of amyloid-β (Aβ) and intracellular inclusions of hyperphosphorylated tau. Although genetic studies of familial Alzheimer's disease suggest a causal link between Aβ and disease symptoms, the failure of various Aβ-Targeted strategies to slow or halt disease progression has led to consideration of the idea that inhibition of tau aggregation might be a more promising therapeutic approach. Methylene blue (MB), which inhibits tau aggregation and rescue memory deficits in a mouse model of tauopathy, however, lacked efficacy in a recent Phase III clinical trial. In order to gain insight into this failure, the present study was designed to examine the mechanism through which MB inhibits tau aggregation. We found that MB inhibits heparin-induced tau aggregation in vitro, as measured by thioflavin T fluorescence. Further, MB reduced the amount of tau in precipitants recovered after ultracentrifugation of the aggregation mixture. Atomic force microscopy revealed that MB reduces the number of tau fibrils but increases the number of granular tau oligomers. The latter result was confirmed by sucrose gradient centrifugation: MB treatmentwas associated with higher levels of granular tau oligomers (fraction 3) and lower levels of tau fibrils (fractions 5 and 6). We previously demonstrated that the formation of granular tau oligomers, rather than tau fibrils, is essential for neuronal death. Thus, the fact that MB actions are limited to inhibition of tau fibril formation provides a mechanistic explanation for the poor performance of MB in the recent Phase III clinical trial.

KW - Alzheimer's disease

KW - Clinical trial

KW - Granular tau oligomer

KW - Inhibitor

KW - Methylene blue

KW - Oligomer

KW - Protein aggregation

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=85064868381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064868381&partnerID=8YFLogxK

U2 - 10.3233/JAD-181001

DO - 10.3233/JAD-181001

M3 - Article

C2 - 30909223

AN - SCOPUS:85064868381

VL - 68

SP - 1677

EP - 1686

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -